Value of immunohistochemical expression of podocalyxin in active lupus nephritis

Behairy, Maha; Shakweer, Marwa M; Said, Tamer Wahid El; El-Gharbawy, Nermin H

doi:10.1016/j.nefro.2017.06.008

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies revealed that podocyte loss indicated by podocalyxin immunohistochemical expression in LN renal biopsy reflects the degree of disease pathological activity and severity and the degree of podocyte effacement by electron microscope (26).…”

Section: Discussionmentioning

confidence: 99%

Urinary podocin; is it a valuable disease activity biomarker in patients with lupus nephritis?

Behairy,

ElShaarawy,

Bawady

et al. 2021

J Nephropathol

View full text Add to dashboard Cite

Introduction: Podocyturia can be considered as a noninvasive marker for evaluation and follow up of glomerular disease progression. Objectives: In this study, we aimed to assess the clinical utility of urinary podocin as an index of lupus nephritis activity. Patients and Methods: This cross-sectional study included 45 patients with systemic lupus erythematosus (SLE). Patients were subdivided into three groups: group (I) 10 SLE, patients without clinical or laboratory evidence of lupus nephritis (LN), which were assessed by Systemic Lupus Activity Measure (SLAM) score of the disease activity. Group (II), which included 15 patients with evident active LN before starting the immunosuppressive induction treatment and group (III) which is consisted of 20 patients with LN in partial or complete remission. Urinary podocin assay was conducted by enzyme-linked immunosorbent assay enzyme-linked immunosorbent assay (ELISA) technique. Results: There was a statistically significant difference between the studied groups regarding urinary podocin levels. The mean of urinary podocin (ng/mL) was (2.29 ± 0.71, 37.20 ± 14.38, 10.5 ±2.30; P≤0.001) in the three groups consecutively, with significant decrease of urinary podocin in LN patients after remission versus high level in patients with active LN. Highly significant positive correlations were found between urinary podocin and global SLAM activity (r = 0.852; P≤ 0.001), SLAM-Renal score (r= 0.854; P≤0.001), urine albumin to creatinine ratio, (mg/g) (r=0.895; P≤0.001). Highly significant negative correlations of urinary podocin and C3 (r=0.803; P≤ 0.001), C4 (r= -0.760; P≤0.001) and eGFR (r = -0.759; P≤0.001) were detected. Conclusion: Urinary podocin as non-invasive biomarker is significantly correlated to SLE disease activity and LN activity measured by global SLAM clinical score with both high sensitivity and specificity. Urinary podocin can be also considered as a prognostic marker in the management of LN patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary podocin; is it a valuable disease activity biomarker in patients with lupus nephritis?

Behairy,

ElShaarawy,

Bawady

et al. 2021

J Nephropathol

View full text Add to dashboard Cite

show abstract

Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study

Wang

Yao

Liu

2020

BioMed Research International

View full text Add to dashboard Cite

This retrospective study investigated whether podocalyxin expression in renal biopsies and urine of patients with diabetic nephropathy (DN) is associated with renal function. This retrospective study included 32 patients with nephropathy, secondary to type 2 diabetes treated at the First Hospital of Lanzhou University (January 2010 to January 2015). Compared with the control group, the DN group had a significantly lower renal expression of podocalyxin and higher urinary podocalyxin/creatinine ratio. Patients with DN were divided into the high and low expression groups according to podocalyxin expression in renal tissues. Patients in the low expression group had longer diabetes duration, lower plasma albumin and eGFR, higher glycated hemoglobin (HbA1c), 24 h urinary protein, serum creatinine, and urinary podocalyxin/creatinine ratio, and more severe glomerular, tubulointerstitial, and renal interstitial inflammation than patients in the high expression group (all P<0.01). The renal survival rate was significantly lower in the low expression group than in the high expression group (P<0.01). Single-factor Cox regression analysis showed that reduced podocalyxin expression and increased urinary podocalyxin excretion were associated with poor renal outcome. Measuring podocalyxin levels in renal tissues and urine could help evaluate the progression of DN.

show abstract

Value of immunohistochemical expression of podocalyxin in active lupus nephritis

Abstract: Podocyte loss indicated by podocalyxin immunohistochemical expression reflects the degree of activity and severity of LN and the degree of podocyte effacement by E/M.

Cited by 2 publications

References 24 publications

Urinary podocin; is it a valuable disease activity biomarker in patients with lupus nephritis?

Urinary podocin; is it a valuable disease activity biomarker in patients with lupus nephritis?

Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study

Contact Info

Product

Resources

About